Immune System News and Research

RSS

Jump starting T cells in skin cancer

Advanced melanoma, the most deadly form of skin cancer, can be successfully treated in some cases by vaccinating patients with tumor proteins.

17 Jan 2005

Researchers have identified the cellular receptor for the JC virus

Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).

17 Jan 2005

Scientists are a step closer to developing drug targets to treat fungal meningitis

Scientists are a step closer to developing drug targets to treat fungal meningitis -- the infection linked to at least three deaths on Vancouver Island -- thanks to the sequencing of two Cryptococcus genomes by an international team that included researchers at the University of British Columbia and the BC Cancer Agency's Michael Smith Genome Sciences Centre in Vancouver.

17 Jan 2005

FDA licenses Sanofi pasteur vaccine for protection against meningococcal disease

Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for protection against meningococcal disease in adolescents and adults aged 11-55 years.

17 Jan 2005

Gene transfer used to deliver antibodies to fight Anthrax

Using gene transfer technology, investigators were able to immunize mice against anthrax in just 12 hours, according to new research featured in the February 2005 issue of Molecular Therapy, the peer-reviewed scientific journal of the American Society of Gene Therapy (ASGT).

12 Jan 2005

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Australian drug specialist Narhex Life Sciences, has announced a partnership with one of the world’s foremost US medical research centres to evaluate its protease inhibitor Nar DG 35 Prodrug for its activity against Hepatitis C and SARS viruses.

12 Jan 2005

Scientists uncover new evidence to help explain statins’ effects in Alzheimer’s disease

Scientists at Jefferson Medical College and the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia have taken another step in understanding the potential effects of anti-cholesterol drugs on Alzheimer’s disease.

12 Jan 2005

Using models to understand malaria

Malaria is one of the world's major killers. More than 500 million people live in epidemic regions and some 2 million - mostly children - die each year. And each year, drug resistance increases in the malarial parasite, Plasmodium falciparum, and the search for new treatments becomes more desperate.

12 Jan 2005

Important clue to understanding the origins of the AIDS epidemic

Medical Research Council (MRC) scientists have uncovered an important clue to understanding the origins of the AIDS epidemic. The work suggests that harnessing natural mechanisms of resistance to HIV infection might provide new methods for combating AIDS.

12 Jan 2005

Safety established for Vaxin's first flu vaccine in clinical trial

Vaxin Inc., a privately-held biotechnology company, has demonstrated, in a Phase I human clinical study, that the company's recombinant influenza vaccine provides a potential alternative to traditional flu vaccines.

12 Jan 2005

Novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some breast cancers

Based on successful animal studies, a novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some human breast cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.

10 Jan 2005

Important clue to understanding the origins of the AIDS epidemic

10 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Millennium Pharmaceuticals today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of VISTA (Velcadeas Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone), a multicenter, international phase III clinical trial of Velcadein combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates.

10 Jan 2005

Key genetic factor determines HIV/AIDS risk

People with more copies of a gene that helps to fight HIV are less likely to become infected with the virus or to develop AIDS than those of the same geographical ancestry, such as European Americans, who have fewer copies of the gene, according to a study funded by the National Institute of Allergy and Infectious Diseases (NIAID).

10 Jan 2005

Core promoter mutants of Hepatitis B Virus e Antigen associated with development of fulminant hepatitis and liver cancer

Scientists in Brown Medical School, Providence, USA, have found that core promoter mutants of Hepatitis B Virus e Antigen replicate at up to 10-fold higher levels in transfected human hepatoma cells than the wild-type virus.

9 Jan 2005

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B. The investigator-initiated study is the largest clinical trial to date with peginterferon alfa-2b therapy for chronic hepatitis B.

7 Jan 2005

Discovery could lead to a screening test that identifies people who have a higher or lower susceptibility to HIV/AIDS

6 Jan 2005

DermaVir, a novel treatment for HIV/AIDS, complements and improves present drug therapies

DermaVir, a novel treatment for HIV/AIDS, offers a new option which complements and improves present drug therapies. The vaccine, applied topically to the skin, has demonstrated efficacy in boosting immune responses and controlling virus replication in chronically infected monkeys.

6 Jan 2005

New hope for millions of patients suffering from liver damage (cirrhosis)

Millions of patients suffering from liver damage (cirrhosis) and failure may benefit from research by the Universities of Edinburgh and Southampton which may lead to new life-saving treatments. There is currently no cure for liver cirrhosis and a patient's only hope of survival is to receive a liver transplant.

5 Jan 2005

Immune System News and Research

Jump starting T cells in skin cancer

Researchers have identified the cellular receptor for the JC virus

Scientists are a step closer to developing drug targets to treat fungal meningitis

FDA licenses Sanofi pasteur vaccine for protection against meningococcal disease

Gene transfer used to deliver antibodies to fight Anthrax

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Scientists uncover new evidence to help explain statins’ effects in Alzheimer’s disease

Using models to understand malaria

Important clue to understanding the origins of the AIDS epidemic

Safety established for Vaxin's first flu vaccine in clinical trial

Novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some breast cancers

Important clue to understanding the origins of the AIDS epidemic

Potential new therapies for cancer and bleeding disorders

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Key genetic factor determines HIV/AIDS risk

Core promoter mutants of Hepatitis B Virus e Antigen associated with development of fulminant hepatitis and liver cancer

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Discovery could lead to a screening test that identifies people who have a higher or lower susceptibility to HIV/AIDS

DermaVir, a novel treatment for HIV/AIDS, complements and improves present drug therapies

New hope for millions of patients suffering from liver damage (cirrhosis)

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News